Katie Nason to Neoadjuvant Therapy
This is a "connection" page, showing publications Katie Nason has written about Neoadjuvant Therapy.
Connection Strength
1.426
-
Nason KS. Is there a role for postinduction positron emission tomography and computed tomography with fludeoxyglucose F 18? A call for standardization. J Thorac Cardiovasc Surg. 2016 Apr; 151(4):980-1.
Score: 0.474
-
Nason KS. Predicting response to neoadjuvant therapy in esophageal cancer with p53 genotyping: a fortune-teller's crystal ball or a viable prognostic tool? J Thorac Cardiovasc Surg. 2014 Nov; 148(5):2286-7.
Score: 0.432
-
Lu M, Luketich JD, Levy RM, Awais O, Sarkaria I, Visintainer P, Nason KS. Anastomotic complications after esophagectomy: Influence of omentoplasty in propensity-weighted cohorts. J Thorac Cardiovasc Surg. 2020 05; 159(5):2096-2105.
Score: 0.155
-
Rocco G, Nason K, Brunelli A, Varela G, Waddell T, Jones DR. Management of stage IIIA (N2) non-small cell lung cancer: A transatlantic perspective. J Thorac Cardiovasc Surg. 2016 May; 151(5):1235-8.
Score: 0.120
-
Zahoor H, Luketich JD, Weksler B, Winger DG, Christie NA, Levy RM, Gibson MK, Davison JM, Nason KS. The revised American Joint Committee on Cancer staging system (7th edition) improves prognostic stratification after minimally invasive esophagectomy for esophagogastric adenocarcinoma. Am J Surg. 2015 Oct; 210(4):610-7.
Score: 0.114
-
Zahoor H, Luketich JD, Levy RM, Awais O, Winger DG, Gibson MK, Nason KS. A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma. J Thorac Cardiovasc Surg. 2015 Feb; 149(2):538-47.
Score: 0.109
-
Schuchert MJ, Souza AP, Abbas G, Pennathur A, Nason KS, Jack R, Horne ZD, Landreneau JR, Santana M, Wilson DO, Luketich JD, Landreneau RJ. Extended Chamberlain minithoracotomy: a safe and versatile approach for difficult lung resections. Ann Thorac Surg. 2012 May; 93(5):1641-5; discussion 1646.
Score: 0.023